| Clinical Trial Name | Clinical Trial Full Title | Principal Investigator | Project site status | Clinical trials gov number |
|---|---|---|---|---|
| (AstraZeneca) D0816L00003 / LIGHT | Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 2 Prior Lines of Chemotherapy | Helpman, Dr Limor | Open to recruitment | NCT02983799 |
| (CCTG) OV.25 / STICs AND STONEs | A Randomized Phase II Double-Blind Placebo-Controlled Trial of Acetylsalicylic Acid (ASA) in Prevention of Ovarian Cancer in Women with BRCA 1/2 Mutations (STICs and STONEs) | Bordeleau, Dr Louise | Open to recruitment | NCT03480776 |
| (UHN) NECO / NEC | A Phase II, Open label Study of the Poly(ADP-ribose) Polymerase Inhibitor Niraparib (MK 4827) in Recurrent Endometrial Cancer | Jimenez, Dr Waldo | Open to recruitment | NCT03016338 |
| (ImmunoGen) IMGN853-0402 | A Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination with Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin, in Adults with Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | Hirte, Dr Hal | Suspended/On hold | NCT02606305 |
| (UHN) PHL-086/NCI 9322 | A Phase II Study of XL-184 (Cabosantinib) In Recurrent or Metastatic Endometrial Cancer | Hirte, Dr Hal | Suspended/On hold | NCT01935934 |
Find a Trial
Contact Us